Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its ...

Augustine Therapeutics NV has synthesized new heteroaryl-amine compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be useful for the treatment of inflammation, autoimmune ...

The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: ...

Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Jiangsu Key Laboratory of Drug Design and ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

With the publication of this study, guselkumab is now the third IL-23 inhibitor to meet its primary efficacy endpoint in this population, joining the already approved mirikizumab and risankizumab. 3,4 ...

Calcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line treatment used to treat and prevent migraines. There are two types of CGRP medications: monoclonal antibodies and ...

School of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia ...

Suzhou Puhe Biopharma Co. Ltd. has disclosed histone deacetylase 1 (HDAC1) inhibitors acting as REST Corepressor 1 (RCOR1; CoREST)/histone deacetylase (HDAC) complex inhibitors reported to be useful ...